Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-1,41%
1 076,13
-15,38
-1,41%
—1 091,511 090,401 090,401 073,69——
SIXC
Communications
SIXC
Communications
SIXC
-0,55%
606,74
-3,37
-0,55%
—610,11610,11610,29606,17——
SIXE
Energy
SIXE
Energy
SIXE
+0,88%
1 248,82
+10,84
+0,88%
—1 237,981 237,831 252,411 225,03——
SIXI
Industrials
SIXI
Industrials
SIXI
-1,17%
1 724,36
-20,35
-1,17%
—1 744,711 740,951 747,291 721,57——
SIXM
Financials
SIXM
Financials
SIXM
-0,72%
635,59
-4,59
-0,72%
—640,18639,92643,19634,73——
SIXR
Staples
SIXR
Staples
SIXR
-0,76%
843,15
-6,43
-0,76%
—849,58845,27851,68839,47——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,55%
216,29
-1,19
-0,55%
—217,48217,48218,16215,51——
SIXT
Technology
SIXT
Technology
SIXT
+0,08%
3 263,41
+2,72
+0,08%
—3 260,693 273,363 287,813 240,78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,34%
939,24
-3,21
-0,34%
—942,45939,39948,80933,98——
SIXV
Health care
SIXV
Health care
SIXV
-0,29%
1 462,56
-4,24
-0,29%
—1 466,801 464,701 467,191 458,36——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,71%
2 380,40
-17,10
-0,71%
—2 397,502 395,032 412,012 370,64——
GSK:NYSE
GSK plc
50,90 $
-1,38%
(-0,71) 1D
50,99 $
+0,18% (+0,090)
After hours
Closed: 4 մյս, 16:00:02 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GSK...
Open
51,52 $
High
51,61 $
Low
50,78 $
Mkt. cap
102,51 մլրդ
Avg. vol.
4,41 մլն
Volume
3,20 մլն
Dividend
3,49%
Quarterly dividend
0,44 $
Ex dividend date
14 մյս, 2026 թ.
P/E ratio
13,17
52-wk high
61,70 $
52-wk low
35,45 $
EPS
3,87 $
Beta
0,29
Shares outstanding
2,03 մլրդ
No. of employees
67 հզր
News stories
From sources across the web
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England. GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK. The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66,8 հզր
Founded27 դեկ, 2000 թ.
Headquarters-
Sector-
Websitegsk.com
Last report
29 ապր, 2026 թ.
Fiscal Period
Q1 2026
Normalized EPS / Estimate
46,50/ (0,44 est.)GBP
+10 388,80%beat
Revenue / Estimate
7,63 մլրդ/ (7,61 մլրդ est.)GBP
+0,22%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in GBP
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
Revenue
7,99 մլրդ
8,55 մլրդ
8,62 մլրդ
7,63 մլրդ
Cost of goods sold
2,16 մլրդ
2,24 մլրդ
2,62 մլրդ
1,87 մլրդ
Cost of revenue
2,16 մլրդ
2,24 մլրդ
2,62 մլրդ
1,87 մլրդ
Research and development expenses
1,54 մլրդ
1,58 մլրդ
2,14 մլրդ
1,52 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,13 մլրդ
2,16 մլրդ
2,67 մլրդ
2,08 մլրդ
Operating expense
3,43 մլրդ
3,23 մլրդ
4,37 մլրդ
2,99 մլրդ
Total operating expenses
5,59 մլրդ
5,46 մլրդ
6,99 մլրդ
4,86 մլրդ
Operating income
2,39 մլրդ
3,08 մլրդ
1,63 մլրդ
2,77 մլրդ
Other non operating income
-
-
-21,00 մլն
-
EBT including unusual items
1,89 մլրդ
2,46 մլրդ
950,00 մլն
2,14 մլրդ
EBT excluding unusual items
2,26 մլրդ
2,94 մլրդ
1,48 մլրդ
2,62 մլրդ
Income tax expense
241,00 մլն
312,00 մլն
223,00 մլն
305,00 մլն
Effective tax rate
12,77%
12,70%
23,47%
14,23%
Other operating expenses
-246,00 մլն
-511,00 մլն
-434,00 մլն
-615,00 մլն
Net income
1,44 մլրդ
2,01 մլրդ
636,00 մլն
1,74 մլրդ
Net profit margin
18,07%
23,55%
7,38%
22,77%
Earnings per share
0,46
0,55
-
-
Interest and investment income
50,00 մլն
26,00 մլն
17,00 մլն
22,00 մլն
Interest expense
-184,00 մլն
-167,00 մլն
-145,00 մլն
-167,00 մլն
Net interest expenses
-134,00 մլն
-141,00 մլն
-128,00 մլն
-145,00 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
3,55 մլրդ
3,82 մլրդ
2,69 մլրդ
3,23 մլրդ
Gain or loss from assets sale
-
-
-40,00 մլն
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer